The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Collateral sensitivity as a strategy against cancer multidrug resistance
Open accessAbstract
While chemotherapy remains the most effective treatment for disseminated tumors, acquired or intrinsic drug resistance accounts for approximately 90% of treatment failure. Multidrug resistance (MDR), the simultaneous resistance to drugs that differ both structurally and mechanistically, often results from drug efflux pumps in the cell membrane that reduce intracellular drug levels to less than therapeutic concentrations. Expression of the MDR transporter P-glycoprotein (P-gp, MDR1, ABCB1) has been shown to correlate with overall poor chemotherapy response and prognosis. This review will focus on collateral sensitivity (CS), the ability of compounds to kill MDR cells selectively over the parental cells from which they were derived. Insights into CS may offer an alternative strategy for the clinical resolution of MDR, as highly selective and potent CS agents may lead to drugs that are effective at MDR cell killing and tumor resensitization. Four main mechanistic hypotheses for CS will be reviewed, followed by a discussion on quantitative and experimental evaluation of CS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Collateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug Tiopronin
Goldsborough, A. S., Handley, M. D., Dulcey, A. E., Pluchino, K. M., Kannan, P., Brimacombe, K. R., Hall, M. D., Griffiths, G. L., & Gottesman, M. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2001663 · Cited by 36
Self-citationRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Self-citationRegulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Self-citationOtto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Self-citationTsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459
Xu, R.-H., Pelicano, H., Zhou, Y., Carew, J. S., Feng, L., Bhalla, K. N., Keating, M. J., & Huang, P. (2005) · Cancer Research · doi:10.1158/0008-5472.613.65.2 · Cited by 835
The Role of ABC Transporters in Clinical Practice
Leonard, G. D., Fojo, T., & Bates, S. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-411 · Cited by 817
Toxic drug effects associated with oxygen metabolism: Redox cycling and lipid peroxidation
Kappus, H., & Sies, H. (1981) · Experientia · doi:10.1007/bf01948335 · Cited by 642
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition
Zhou, S.-F. (2008) · Xenobiotica · doi:10.1080/00498250701867889 · Cited by 599
Predicting drug sensitivity and resistance
Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.026 · Cited by 531
Self-citationIsolation and genetic characterization of human KB cell lines resistant to multiple drugs
Akiyama, S.-I., Fojo, A., Hanover, J. A., Pastan, I., & Gottesman, M. M. (1985) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01534700 · Cited by 529
Self-citationWhitnall, M., Howard, J., Ponka, P., & Richardson, D. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604979103 · Cited by 509
The role of iron in cell cycle progression and the proliferation of neoplastic cells
Le, N. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00068-9 · Cited by 453
Szybalski, W., & Bryson, V. (1952) · Journal of Bacteriology · doi:10.1128/jb.64.4.489-499.1952 · Cited by 421
ABCG2: determining its relevance in clinical drug resistance
Robey, R. W., Polgar, O., Deeken, J., To, K. W., & Bates, S. E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9042-6 · Cited by 387
Yuan, J., Lovejoy, D. B., & Richardson, D. R. (2004) · Blood · doi:10.1182/blood-2004-03-0868 · Cited by 381
Tsuruo, T., Iida, H., Nojiri, M., Tsukagoshi, S., & Sakurai, Y. (1983) · PubMed · Cited by 379
Transport of glutathione and glutathione conjugates by MRP1
Cole, S. P. C., & Deeley, R. G. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.06.008 · Cited by 369
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Fox, E., & Bates, S. E. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.447 · Cited by 350
Le, N. T. V., & Richardson, D. R. (2004) · Blood · doi:10.1182/blood-2004-05-1866 · Cited by 321
Pleiotropic phenotype of colchicine‐resistant CHO cells: Cross‐resistance and collateral sensitivity
Bech‐Hansen, N. T., Till, J. E., & Ling, V. (1976) · Journal of Cellular Physiology · doi:10.1002/jcp.1040880104 · Cited by 309
Is resistance useless? Multidrug resistance and collateral sensitivity
Hall, M. D., Handley, M. D., & Gottesman, M. M. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.003 · Cited by 259
Self-citationCharacterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein.
al-Shawi, M. K., & Senior, A. E. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53597-3 · Cited by 222
Nobili, S., Landini, I., Mazzei, T., & Mini, E. (2012) · Medicinal Research Reviews · doi:10.1002/med.20239 · Cited by 182
Ludwig, J. A., Szakács, G., Martin, S. E., Chu, B. F., Cardarelli, C., Sauna, Z. E., Caplen, N. J., Fales, H. M., Ambudkar, S. V., Weinstein, J. N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3322 · Cited by 176
Self-citationKelly, R. J., Draper, D., Chen, C. C., Robey, R. W., Figg, W. D., Piekarz, R. L., Chen, X., Gardner, E. R., Balis, F. M., Venkatesan, A. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1725 · Cited by 172
Hall, M. D., Salam, N. K., Hellawell, J. L., Fales, H. M., Kensler, C. B., Ludwig, J. A., Szakács, G., Hibbs, D. E., & Gottesman, M. M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800861c · Cited by 167
Self-citationVerapamil Stimulates Glutathione Transport by the 190-kDa Multidrug Resistance Protein 1 (MRP1)
Loe, D. W., Deeley, R. G., & Cole, S. P. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39265-1 · Cited by 159
Action of calcium antagonists on multidrug resistant cells
Cano-Gauci, D. F., & Riorda, J. R. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90139-0 · Cited by 148
Berger, W., Setinek, U., Hollaus, P. H., Zidek, T., Steiner, E., Elbling, L., Cantonati, H., Attems, J., Gsur, A., & Micksche, M. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0653-9 · Cited by 142
Trompier, D., Chang, X.-B., Barattin, R., d′Hardemare, A. D. M., Pietro, A. D., & Baubichon-Cortay, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0143 · Cited by 127
Kaplan, O., Navon, G., Lyon, R. C., Faustino, P. J., Straka, E. J., & Cohen, J. S. (1990) · PubMed · Cited by 124
Lyon, R. C., Cohen, J. S., Faustino, P. J., Mégnin-Chanet, F., & Myers, C. E. (1988) · PubMed · Cited by 122
Hall, M. D., Brimacombe, K. R., Varonka, M. S., Pluchino, K. M., Monda, J. K., Li, J., Walsh, M. J., Boxer, M. B., Warren, T. H., Fales, H. M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006047 · Cited by 116
Self-citationInduction by verapamil of a rapid increase in ATP consumption in multidrug‐resistant tumor cells
Broxterman, H. J., Pinedo, H. M., Kuiper, C. M., Kaptein, L. C. M., Schuurhuis, G. J., & Lankelma, J. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.7.3350243 · Cited by 111
Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells
Türk, D., Hall, M. D., Chu, B. F., Ludwig, J. A., Fales, H. M., Gottesman, M. M., & Szakács, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2422 · Cited by 109
Self-citationSearching for synthetic lethality in cancer
Brough, R., Frankum, J. R., Costa-Cabral, S., Lord, C. J., & Ashworth, A. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.009 · Cited by 107
Wu, C., Shukla, S., Calcagno, A. M., Hall, M. D., Gottesman, M. M., & Ambudkar, S. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2005 · Cited by 100
Self-citationA Mechanism for P-Glycoprotein-Mediated Apoptosis As Revealed by Verapamil Hypersensitivity
Karwatsky, J., Lincoln, M. C., & Georges, E. (2003) · Biochemistry · doi:10.1021/bi034149+ · Cited by 87
Verapamil decreases P‐glycoprotein expression in multidrug‐resistant human leukemic cell lines
Muller, C., Bailly, J., Goubin, F., Laredo, J., Jaffrézou, J., Bordier, C., & Laurent, G. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560523 · Cited by 82
The Challenge of Exploiting ABCG2 in the Clinic
Robey, R. W., Ieranò, C., Zhan, Z., & Bates, S. E. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795163913 · Cited by 78
Structure of a multidrug transporter
Gottesman, M. M., Ambudkar, S. V., & Xia, D. (2009) · Nature Biotechnology · doi:10.1038/nbt0609-546 · Cited by 77
Self-citationRole of Reduced Glutathione Efflux in Apoptosis of Immortalized Human Keratinocytes Induced by UVA
He, Y., Huang, J.-L., Ramírez, D. C., & Chignell, C. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207781200 · Cited by 74
The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study
Jansson, P. J., Hawkins, C. L., Lovejoy, D. B., & Richardson, D. R. (2010) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2010.07.012 · Cited by 72
(R)- and (S)-Verapamil Differentially Modulate the Multidrug-resistant Protein MRP1
Perrotton, T., Trompier, D., Chang, X.-B., Pietro, A. D., & Baubichon-Cortay, H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703964200 · Cited by 70
Alemán, C., Annereau, J.-P., Liang, X., et al. (2003) · PubMed · Cited by 67
Calcagno, A. M., Kim, I., Wu, C., Shukla, S., & Ambudkar, S. V. (2007) · Current Drug Delivery · doi:10.2174/156720107782151241 · Cited by 58
Calcium Channel Blocker Enhancement of Anticancer Drug Cytotoxicity—A Review
Helson, L. (1984) · Cancer Drug Delivery · doi:10.1089/cdd.1984.1.353 · Cited by 50
Kaplan, O., Jaroszewski, J. W., Clarke, R. C., Fairchild, C. R., Schoenlein, P. V., Goldenberg, S., Gottesman, M. M., & Cohen, J. S. (1991) · PubMed · Cited by 49
Self-citationBell, S., Quinn, D., Kellett, G. L., & Warr, J. R. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.708 · Cited by 48
Ganguly, A., Basu, S., Chakraborty, P., Chatterjee, S., Sarkar, A., Chatterjee, M., & Choudhuri, S. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011253 · Cited by 46
Marks, K. M., Park, E. S., Arefolov, A., Russo, K., Ishihara, K., Ring, J. E., Clardy, J., Clarke, A. S., & Pelish, H. E. (2011) · Journal of Natural Products · doi:10.1021/np100429s · Cited by 45
Laberge, R.-M., Ambadipudi, R., & Georges, E. (2009) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2009.09.012 · Cited by 43
Prisant, L. M. (2001) · Heart Disease · doi:10.1097/00132580-200101000-00008 · Cited by 40
The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation
Bentley, J. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)04739-3 · Cited by 38
Tran, V. H., Marks, D. C., Duke, R. K., Bebawy, M., Duke, C. C., & Roufogalis, B. D. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.535959 · Cited by 36
Antitumor Agents 260. New Desmosdumotin B Analogues with Improved In Vitro Anticancer Activity
Nakagawa‐Goto, K., Bastow, K. F., Chen, T.-H., Morris-Natschke, S. L., & Lee, K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701208v · Cited by 30
Genoux‐Bastide, E., Lorendeau, D., Nicolle, E., Yahiaoui, S., Magnard, S., Pietro, A. D., Baubichon-Cortay, H., & Boumendjel, A. (2011) · ChemMedChem · doi:10.1002/cmdc.201100102 · Cited by 30
Callaghan, R., & Riordan, J. R. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00042-2 · Cited by 29
Self-citationBarattin, R., Perrotton, T., Trompier, D., Lorendeau, D., Pietro, A. D., d′Hardemare, A. D. M., & Baubichon-Cortay, H. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.07.031 · Cited by 25
Antitumor Agents. 280. Multidrug Resistance-Selective Desmosdumotin B Analogues
Nakagawa‐Goto, K., Chang, P.-C., Lai, C.-Y., Hung, H., Chen, T.-H., Wu, P.-C., Zhu, H., Sedykh, A., Bastow, K. F., & Lee, K. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100846r · Cited by 24
Cited by
Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Multidrug evolutionary strategies to reverse antibiotic resistance
Baym, M., Stone, L. K., & Kishony, R. (2016) · Science · doi:10.1126/science.aad3292 · Cited by 710
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Mechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660
Imamovic, L., & Sommer, M. O. A. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006609 · Cited by 444
Metadata
- Authors
- Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., & Gottesman, M. M.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 15
- Issue
- 1-2
- Pages
- 98-105
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2019490712
- Cited by
- 305
- References
- 65
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.